Xiaojianzhong decoction attenuates aspirin-induced gastric mucosal injury via the PI3K/AKT/mTOR/ULK1 and AMPK/ULK1 pathways
CONTEXT: Xiaojianzhong decoction (XJZD), classically prescribed in Chinese medicine, has protective and healing effects on gastric mucosal injury. However, the exact mechanism behind this effect remains unclear.
OBJECTIVE: To investigate the effect of XJZD on gastric mucosal injury and explore its underlying mechanisms.
MATERIALS AND METHODS: C57BL/6 mice were randomized into six groups (n = 10): the control group receiving sterile water, the model (aspirin 300 mg/kg), the XJZD high-dose (12 g/kg), XJZD medium-dose (6 g/kg), XJZD low-dose (3 g/kg) and omeprazole (20 mg/kg) groups, by gavage daily for 14 days. The area of gastric mucosal injury, mucosal injury index and degree of histopathological damage were analysed. Gastric mucosal epithelial cell apoptosis was detected. Epithelial cell autophagy was observed. The expression levels of tight junction proteins and proteins related to apoptosis, autophagy and the pentose phosphate pathway were analysed.
RESULTS: The results showed that after treatment with XJZD (12, 6 and 3 g/kg), the mucosal injury area was reduced (83.4%, 22.6% and 11.3%), the expression level of ZO-1 and occludin was up-regulated, the apoptosis rate of epithelial cells was reduced (40.8%, 25.4% and 8.7%), the expression of autophagy-related proteins LC3 and Beclin1 was decreased and the expression of p62 was increased, the PI3K/AKT/mTOR/ULK1(ser757) signalling pathway was activated, and the AMPK/ULK1(ser317) signalling pathway was inhibited. In addition, XJZD can antagonize the imbalance of redox homeostasis caused by aspirin and protect the gastric mucosa.
DISCUSSION AND CONCLUSIONS: XJZD protects against aspirin-induced gastric mucosal injury, implying it to be a potential therapeutic agent.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Pharmaceutical biology - 61(2023), 1 vom: 19. Dez., Seite 1234-1248 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Ting [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.08.2023 Date Revised 24.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/13880209.2023.2243998 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36101077X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36101077X | ||
| 003 | DE-627 | ||
| 005 | 20231226084236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13880209.2023.2243998 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM36101077X | ||
| 035 | |a (NLM)37602379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Ting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Xiaojianzhong decoction attenuates aspirin-induced gastric mucosal injury via the PI3K/AKT/mTOR/ULK1 and AMPK/ULK1 pathways |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.08.2023 | ||
| 500 | |a Date Revised 24.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Xiaojianzhong decoction (XJZD), classically prescribed in Chinese medicine, has protective and healing effects on gastric mucosal injury. However, the exact mechanism behind this effect remains unclear | ||
| 520 | |a OBJECTIVE: To investigate the effect of XJZD on gastric mucosal injury and explore its underlying mechanisms | ||
| 520 | |a MATERIALS AND METHODS: C57BL/6 mice were randomized into six groups (n = 10): the control group receiving sterile water, the model (aspirin 300 mg/kg), the XJZD high-dose (12 g/kg), XJZD medium-dose (6 g/kg), XJZD low-dose (3 g/kg) and omeprazole (20 mg/kg) groups, by gavage daily for 14 days. The area of gastric mucosal injury, mucosal injury index and degree of histopathological damage were analysed. Gastric mucosal epithelial cell apoptosis was detected. Epithelial cell autophagy was observed. The expression levels of tight junction proteins and proteins related to apoptosis, autophagy and the pentose phosphate pathway were analysed | ||
| 520 | |a RESULTS: The results showed that after treatment with XJZD (12, 6 and 3 g/kg), the mucosal injury area was reduced (83.4%, 22.6% and 11.3%), the expression level of ZO-1 and occludin was up-regulated, the apoptosis rate of epithelial cells was reduced (40.8%, 25.4% and 8.7%), the expression of autophagy-related proteins LC3 and Beclin1 was decreased and the expression of p62 was increased, the PI3K/AKT/mTOR/ULK1(ser757) signalling pathway was activated, and the AMPK/ULK1(ser317) signalling pathway was inhibited. In addition, XJZD can antagonize the imbalance of redox homeostasis caused by aspirin and protect the gastric mucosa | ||
| 520 | |a DISCUSSION AND CONCLUSIONS: XJZD protects against aspirin-induced gastric mucosal injury, implying it to be a potential therapeutic agent | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Traditional Chinese medicine | |
| 650 | 4 | |a apoptotic | |
| 650 | 4 | |a autophagy | |
| 650 | 4 | |a drug-induced gastric injury | |
| 650 | 4 | |a redox homeostasis | |
| 650 | 7 | |a AMP-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.31 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 700 | 1 | |a Bao, Shengchuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jiaxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Hailiang |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jingtao |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Shuguang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical biology |d 1997 |g 61(2023), 1 vom: 19. Dez., Seite 1234-1248 |w (DE-627)NLM097504416 |x 1744-5116 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:1 |g day:19 |g month:12 |g pages:1234-1248 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13880209.2023.2243998 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 1 |b 19 |c 12 |h 1234-1248 | ||